223
Participants
Start Date
September 30, 2010
Primary Completion Date
December 31, 2013
Study Completion Date
February 28, 2014
Docetaxel
PX-866
Beth Israel Hospital, New York
New York University Medical Center, New York
Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
New York Oncology, Hematology, Latham
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania, Philadelphia
John Hopkins University, Baltimore
Virginia Cancer Specialists, Fairfax
Virginia Oncology Associates, Newport News
Oncology and Hematology Associates of SW Virginia, DBA Blue Ridge Cancer Care, Christiansburg
Medical University of South Carolina, Charleston
Cancer Center of Pasco-Pinellas, Holiday
University of Alabama at Birmingham, Birmingham
Washington University, St Louis
Cancer Center of Kansas, Wichita
Mary Crowley Cancer Center, Dallas
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - South Austin, Austin
University of Colorado Cancer Center, Aurora
Eastern Colorado Health Care System - Denver VA, Denver
New Mexico Cancer Care Alliance, Albuquerque
Southwest Cancer Care, Escondido
Bay Area Cancer Research Group, LLC, Pleasant Hill
Northwest Cancer Specialists, Tualatin
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Medical Oncology Associates, Spokane
Columbia Basin Hematology & Oncology, Kennewick
Cancer Care Manitoba, Winnipeg
London Regional Cancer Program, London
Jewish General Hospital, Montreal
CHUS Hopital Fleurimont, Sherbrooke
Lead Sponsor
Cascadian Therapeutics Inc.
INDUSTRY